Atherosclerosis Treatment Drugs Market -Size, Share, Outlook, and Opportunity Analysis 2018 – 2026

@

Atherosclerosis is characterized by the narrowing and hardening of the arteries. In this condition, arteries become blocked by fatty substances, such as cholesterol. These substances are called as plaques or atheroma. The risks of atherosclerosis increase with age. The deposition of plaque tends to narrow the arterial canal, which result in the limited flow of blood and oxygen through it. Atherosclerosis commences with damage to the endothelium of arteries leading to the formation of plaque. This condition is dangerous for the vital organs such as heart and brain. The risk associated with atherosclerosis includes serious cardiovascular and brain diseases. Collectively, these conditions are more common for cardiovascular diseases (CVD) including coronary heart disease, angina pectoris, and transitory ischemia. Other risks for atherosclerosis are carotid artery disease, kidney disease, and peripheral artery disease.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2430

Atherosclerosis Treatment Drugs Market – Driver

Increasing number of pipeline studies and rising involvement of key players for developing the treatment options for atherosclerosis are expected to propel atherosclerosis treatment drugs market growth. For Instance, in November 13, 2018, Bayer in collaboration with Janssen, LP started the clinical study for Rivaroxaban and Acetylsalicylic Acid to build up the insights in treatment patterns and to study results of Rivaroxaban (Xarelto) in combination with acetylsalicylic acid (xatoa) prescribed to patients with atherosclerosis. The study is estimated to complete in August 2021.

Moreover, technological advancement in the atherosclerosis treatment procedures is expected to boost the atherosclerosis treatments drug market growth. For instance, in May 2017, Researchers at Ben-Gurion University (BGU) and the Sheba Medical Center developed Nano polymer therapy, a new therapy for the treatment of atherosclerosis. It prevents heart failure with a new biomedical polymer (E-selectin-targeting polymer) that reduces arterial plaque and inflammation in the cardiovascular system. E-selectin-targeting polymer helps to reduce existing plaque and impedes the further plaque formation. It also prevents arterial thrombosis, ischemia, myocardial infarction, and strokes.

Atherosclerosis Treatment Drugs Market- Restraints

However, the side effects associated with atherosclerosis drugs and limited efficacy of the drugs is expected to hamper atherosclerosis market growth. For instance, in November 2016, The Lancet led by Rory Collins, provided an evidence on statin therapy and the methodological limitations. As per data, statins are associated with increased incidence of diabetes and hemorrhagic stroke. Statins tends to increase the risk of type 2 diabetes in a dose-dependent mode.

Atherosclerosis Treatment Drugs Market- Regional Analysis

On the basis of region, the global atherosclerosis treatment drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Geographically, North America is expected to gain significant market share over the forecast period, owing to increasing incidences of atherosclerotic condition among the population in this region. For instance, in November 2016, as per data provided by the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), there were more than 15.5 million Americans who had coronary artery disease and it is expected that for every 42 seconds an American will experience the onset of a myocardial infarction.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2430

Furthermore, Asia Pacific is expected to witness significant growth in the market, owing to expansion of major key players in this region. For instance, in October 2017, GSK opened its new regional headquarters for Asia in Singapore. The GSK’s purpose for building headquarters is to support the pharmaceutical, vaccines, and consumer healthcare businesses across multiple regions in Asia Pacific.

Key players operating in the Atherosclerosis treatment drugs market include GlaxoSmithKline plc. Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc., Anthera Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company, and Cardium Therapeutics.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Healthcare related news and fitness trends